These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23258964)

  • 1. A pharmacoeconomic analysis of in-hospital costs resulting from reintubation in preterm infants treated with lucinactant, beractant, or poractant alfa.
    Guardia CG; Moya FR; Sinha S; Simmons PD; Segal R; Greenspan JS
    J Pediatr Pharmacol Ther; 2012 Jul; 17(3):220-7. PubMed ID: 23258964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative pharmacoeconomic assessment of two surfactants for the prevention of respiratory distress syndrome.
    Gdovin JM; Moya F; Vishalpura T; Grogg A
    J Pediatr Pharmacol Ther; 2006 Jan; 11(1):43-54. PubMed ID: 23118645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials.
    Moya F; Sinha S; Gadzinowski J; D'Agostino R; Segal R; Guardia C; Mazela J; Liu G;
    Pediatrics; 2007 Jun; 119(6):e1361-70. PubMed ID: 17533176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
    Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
    Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants.
    Moya FR; Gadzinowski J; Bancalari E; Salinas V; Kopelman B; Bancalari A; Kornacka MK; Merritt TA; Segal R; Schaber CJ; Tsai H; Massaro J; d'Agostino R;
    Pediatrics; 2005 Apr; 115(4):1018-29. PubMed ID: 15805380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.
    Fujii A; Allen R; Doros G; O'Brien S
    J Perinatol; 2010 Oct; 30(10):671-6. PubMed ID: 20336077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health Economic Studies of Surfactant Replacement Therapy in Neonates with Respiratory Distress Syndrome: A Systematic Literature Review.
    Magni T; Ragni C; Pelizzi N; Sharma S; Perez-Kempner L; Turkstra E; Nathani J; Orlovic M; Meshchenkova N
    Pharmacoecon Open; 2023 May; 7(3):359-371. PubMed ID: 36906631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poractant Alfa Versus Beractant for Neonatal Respiratory Distress Syndrome: A Retrospective Cost Analysis.
    Brown S; Hurren J; Sartori H
    J Pediatr Pharmacol Ther; 2018; 23(5):367-371. PubMed ID: 30429690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome.
    Dizdar EA; Sari FN; Aydemir C; Oguz SS; Erdeve O; Uras N; Dilmen U
    Am J Perinatol; 2012 Feb; 29(2):95-100. PubMed ID: 22105435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Efficacy and Pharmacoeconomic Outcomes Between Calfactant and Poractant Alfa in Preterm Infants With Respiratory Distress Syndrome.
    Bui A; Schumann C; Le J; Jones T; Schwendeman C
    J Pediatr Pharmacol Ther; 2024 Jun; 29(3):241-247. PubMed ID: 38863863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants.
    Ramanathan R; Rasmussen MR; Gerstmann DR; Finer N; Sekar K;
    Am J Perinatol; 2004 Apr; 21(3):109-19. PubMed ID: 15085492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome.
    Fujii AM; Patel SM; Allen R; Doros G; Guo CY; Testa S
    J Perinatol; 2010 Oct; 30(10):665-70. PubMed ID: 20336076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poractant alfa versus beractant for respiratory distress syndrome in preterm infants: a retrospective cohort study.
    Paul S; Rao S; Kohan R; McMichael J; French N; Zhang G; Simmer K
    J Paediatr Child Health; 2013 Oct; 49(10):839-44. PubMed ID: 23802801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of efficacy between beractant and poractant alfa in respiratory distress syndrome among preterm infants (28-33
    Zamal A; Sk MH; Saha B; Hazra A
    J Perinatol; 2024 Apr; ():. PubMed ID: 38609483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health Economics and Outcomes of Surfactant Treatments for Respiratory Distress Syndrome Among Preterm Infants in US Level III/IV Neonatal Intensive Care Units.
    Sekar K; Fuentes D; Krukas-Hampel MR; Ernst FR
    J Pediatr Pharmacol Ther; 2019; 24(2):117-127. PubMed ID: 31019404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of two different early rescue surfactant treatments on mortality in preterm infants with respiratory distress syndrome.
    Kadıoğlu Şimşek G; Kanmaz Kutman HG; Canpolat FE; Oğuz ŞS
    Clin Respir J; 2020 Mar; 14(3):285-290. PubMed ID: 31814293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose Effect of Poractant Alfa in Neonatal RDS: Analysis of Combined Data from Three Prospective Studies.
    Królak-Olejnik B; Hożejowski R; Szczapa T
    Front Pediatr; 2020; 8():603716. PubMed ID: 33330292
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative efficacy of pulmonary surfactant in respiratory distress syndrome in preterm infants: a Bayesian network meta-analysis.
    Qiu C; Ma C; Fan N; Zhang X; Zheng G
    Arch Med Sci; 2023; 19(5):1446-1453. PubMed ID: 37732036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lucinactant attenuates pulmonary inflammatory response, preserves lung structure, and improves physiologic outcomes in a preterm lamb model of RDS.
    Wolfson MR; Wu J; Hubert TL; Gregory TJ; Mazela J; Shaffer TH
    Pediatr Res; 2012 Oct; 72(4):375-83. PubMed ID: 22821059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early surfactant administration with brief ventilation vs selective surfactant and continued mechanical ventilation for preterm infants with or at risk for RDS.
    Stevens TP; Blennow M; Soll RF
    Cochrane Database Syst Rev; 2002; (2):CD003063. PubMed ID: 12076469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.